News Conference News EAS 2022 FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses Michael O'Riordan May 26, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2019 CHD Mortality Significantly Elevated in Patients With Severe FH Michael O'Riordan May 29, 2019
News Conference News EAS 2019 Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis Michael O'Riordan May 28, 2019